Avoiding the Wrong Medication is the Best Place to Start: CNS Response Congressional Testimony on Suicide Prevention

ALISO VIEJO, Calif., Nov 20, 2014 (GLOBE NEWSWIRE via COMTEX) CNS Response, Inc. (OTCBB:CNSO) CNS Response Chairman Thomas Tierney and CEO George Carpenter provided testimony in support of HR 5059, the Clay Hunt Suicide Prevention for American Veterans Act, at the request of the of the House Veterans Affairs Health Subcommittee on Health. In July, the company provided testimony to the Veterans Affairs Committee, noting the growing role of predictive analytics in reducing harm from mental health medications chosen by trial and error. Thomas Tierney said, The news today is very positive, and it is our belief that HR 5059 may accelerate adoption of predictive analytic tools like PEER. Unlike most areas of medicine, treatments in mental health are often not guided by any physical measure of brain function. PEER is a clinical registry and recommendation engine which provides physicians with objective information on medication response. Previous PEER trials have demonstrated that doctors wi
http://bit.ly/1x4Q6KW